-+ 0.00%
-+ 0.00%
-+ 0.00%
Cue Biopharma: CUE-221 reached a major endpoint in clinical trials of chronic spontaneous urticaria.
Share
Listen to the news
Cue Biopharma: CUE-221 reached a major endpoint in clinical trials of chronic spontaneous urticaria.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending